The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen and 19% for patients who did not receive tamoxifen, a statistically significant difference.

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...